154 related articles for article (PubMed ID: 18627344)
1. Development of peptides specifically modulating the activity of KLK2 and KLK3.
Koistinen H; Närvänen A; Pakkala M; Hekim C; Mattsson JM; Zhu L; Laakkonen P; Stenman UH
Biol Chem; 2008 Jun; 389(6):633-42. PubMed ID: 18627344
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of peptides as protease inhibitors and stimulators.
Koistinen H; Hekim C; Wu P; Närvänen A; Stenman UH
Methods Mol Biol; 2014; 1088():147-58. PubMed ID: 24146402
[TBL] [Abstract][Full Text] [Related]
3. Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors.
Pakkala M; Hekim C; Soininen P; Leinonen J; Koistinen H; Weisell J; Stenman UH; Vepsäläinen J; Närvänen A
J Pept Sci; 2007 May; 13(5):348-53. PubMed ID: 17436344
[TBL] [Abstract][Full Text] [Related]
4. Identification of IGFBP-3 fragments generated by KLK2 and prevention of fragmentation by KLK2-inhibiting peptides.
Hekim C; Riipi T; Weisell J; Närvänen A; Koistinen R; Stenman UH; Koistinen H
Biol Chem; 2010 Apr; 391(4):475-9. PubMed ID: 20180640
[TBL] [Abstract][Full Text] [Related]
5. Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4.
Swedberg JE; Nigon LV; Reid JC; de Veer SJ; Walpole CM; Stephens CR; Walsh TP; Takayama TK; Hooper JD; Clements JA; Buckle AM; Harris JM
Chem Biol; 2009 Jun; 16(6):633-43. PubMed ID: 19549601
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases.
Lawrence MG; Veveris-Lowe TL; Whitbread AK; Nicol DL; Clements JA
Cells Tissues Organs; 2007; 185(1-3):111-5. PubMed ID: 17587816
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic properties of prostate-specific antigen (PSA).
Mattsson JM; Laakkonen P; Stenman UH; Koistinen H
Scand J Clin Lab Invest; 2009; 69(4):447-51. PubMed ID: 19551556
[TBL] [Abstract][Full Text] [Related]
8. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries.
Matsumura M; Bhatt AS; Andress D; Clegg N; Takayama TK; Craik CS; Nelson PS
Prostate; 2005 Jan; 62(1):1-13. PubMed ID: 15389820
[TBL] [Abstract][Full Text] [Related]
9. Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
Bonk S; Kluth M; Jansen K; Hube-Magg C; Makrypidi-Fraune G; Höflmayer D; Weidemann S; Möller K; Uhlig R; Büscheck F; Luebke AM; Burandt E; Clauditz TS; Steurer S; Schlomm T; Huland H; Heinzer H; Sauter G; Simon R; Dum D
Prostate; 2020 Sep; 80(13):1097-1107. PubMed ID: 32628300
[TBL] [Abstract][Full Text] [Related]
10. The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition.
Whitbread AK; Veveris-Lowe TL; Lawrence MG; Nicol DL; Clements JA
Biol Chem; 2006 Jun; 387(6):707-14. PubMed ID: 16800731
[TBL] [Abstract][Full Text] [Related]
11. Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches.
Veveris-Lowe TL; Kruger SJ; Walsh T; Gardiner RA; Clements JA
Semin Thromb Hemost; 2007 Feb; 33(1):87-99. PubMed ID: 17253195
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.
Sävblom C; Halldén C; Cronin AM; Säll T; Savage C; Vertosick EA; Klein RJ; Giwercman A; Lilja H
Clin Chem; 2014 Mar; 60(3):490-9. PubMed ID: 24270797
[TBL] [Abstract][Full Text] [Related]
13. KLK-targeted Therapies for Prostate Cancer.
Hannu K; Johanna M; Ulf-Håkan S
EJIFCC; 2014 Sep; 25(2):207-18. PubMed ID: 27683469
[TBL] [Abstract][Full Text] [Related]
14. Novel small molecule inhibitors for prostate-specific antigen.
Koistinen H; Wohlfahrt G; Mattsson JM; Wu P; Lahdenperä J; Stenman UH
Prostate; 2008 Aug; 68(11):1143-51. PubMed ID: 18500692
[TBL] [Abstract][Full Text] [Related]
15. Mimetics of the disulfide bridge between the N- and C-terminal cysteines of the KLK3-stimulating peptide B-2.
Pakkala M; Weisell J; Hekim C; Vepsäläinen J; Wallen EA; Stenman UH; Koistinen H; Närvänen A
Amino Acids; 2010 Jun; 39(1):233-42. PubMed ID: 19967419
[TBL] [Abstract][Full Text] [Related]
16. Gene expression changes associated with the anti-angiogenic activity of kallikrein-related peptidase 3 (KLK3) on human umbilical vein endothelial cells.
Mattsson JM; Laakkonen P; Kilpinen S; Stenman UH; Koistinen H
Biol Chem; 2008 Jun; 389(6):765-71. PubMed ID: 18627292
[TBL] [Abstract][Full Text] [Related]
17. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies.
Avgeris M; Mavridis K; Scorilas A
Biol Chem; 2010 May; 391(5):505-11. PubMed ID: 20302518
[TBL] [Abstract][Full Text] [Related]
18. Peptides binding to prostate-specific antigen enhance its antiangiogenic activity.
Mattsson JM; Närvänen A; Stenman UH; Koistinen H
Prostate; 2012 Oct; 72(14):1588-94. PubMed ID: 22430591
[TBL] [Abstract][Full Text] [Related]
19. Development of molecules stimulating the activity of KLK3 - an update.
Koistinen H; Wallén E; Ylikangas H; Meinander K; Lahtela-Kakkonen M; Närvänen A; Stenman UH
Biol Chem; 2016 Dec; 397(12):1229-1235. PubMed ID: 27383882
[TBL] [Abstract][Full Text] [Related]
20. Evolution of kallikrein-related peptidases in mammals and identification of a genetic locus encoding potential regulatory inhibitors.
Lundwall A; Clauss A; Olsson AY
Biol Chem; 2006 Mar; 387(3):243-9. PubMed ID: 16542144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
